Evidence map›Paper›PMID 20161785›Full record

ArticlePloS one2010

Human cord blood-derived AC133+ progenitor cells preserve endothelial progenitor characteristics after long term in vitro expansion.

Branislava Janic, Austin M Guo, A S M Iskander, Nadimpalli Ravi S Varma, Alfonso G Scicli, Ali S Arbab

Abstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Branislava JanicCellular and Molecular Imaging Laboratory, Department of Radiology, Henry Ford Hospital, Detroit, Michigan, United States of America. bjanic@rad.hfh.edu
Austin M Guo
A S M Iskander
Nadimpalli Ravi S Varma
Alfonso G Scicli
Ali S Arbab

Funding

Cellular MRI in Glioma and Radiation NecrosisR01CA122031 · NCI · HENRY FORD HEALTH SYSTEM · PI ARBAB, ALI SYED · 2007 to 2010
$992k
Stem Cells as Delivery Vehicles and Imaging Probes for Glioma Gene TherapyR21CA129801 · NCI · HENRY FORD HEALTH SYSTEM · PI ARBAB, ALI SYED · 2008 to 2009
$359k
Differentiation of Glioma from Radiation Injury Using Cellular MRIR21NS058589 · NINDS · HENRY FORD HEALTH SYSTEM · PI ARBAB, ALI SYED · 2007 to 2008
$349k
NCI NIH HHS R01 CA122031NCI NIH HHS R01CA122031NCI NIH HHS R21 CA129801NCI NIH HHS R21CA129801NINDS NIH HHS R21 NS058589NINDS NIH HHS R21NS058589
6 · The paper itself

Abstract

backgroundStem cells/progenitors are central to the development of cell therapy approaches for vascular ischemic diseases. The crucial step in rescuing tissues from ischemia is improvement of vascularization that can be achieved by promoting neovascularization. Endothelial progenitor cells (EPCs) are the best candidates for developing such an approach due to their ability to self-renew, circulate and differentiate into mature endothelial cells (ECs). Studies showed that intravenously administered progenitors isolated from bone marrow, peripheral or cord blood home to ischemic sites. However, the successful clinical application of such transplantation therapy is limited by low quantities of EPCs that can be generated from patients. Hence, the ability to amplify the numbers of autologous EPCs by long term in vitro expansion while preserving their angiogenic potential is critically important for developing EPC based therapies. Therefore, the objective of this study was to evaluate the capacity of cord blood (CB)-derived AC133+ cells to differentiate, in vitro, towards functional, mature endothelial cells (ECs) after long term in vitro expansion. METHODOLOGY: We systematically characterized the properties of CB AC133+ cells over the 30 days of in vitro expansion. During 30 days of culturing, CB AC133+ cells exhibited significant growth potential that was manifested as 148-fold increase in cell numbers. Flow cytometry and immunocytochemistry demonstrated that CB AC133+ cells' expression of endothelial progenitor markers was not affected by long term in vitro culturing. After culturing under EC differentiation conditions, cells exhibited high expression of mature ECs markers, such as CD31, VEGFR-2 and von Willebrand factor, as well as the morphological changes indicative of differentiation towards mature ECs. In addition, throughout the 30 day culture cells preserved their functional capacity that was demonstrated by high uptake of DiI fluorescently conjugated-acetylated-low density lipoprotein (DiI-Ac-LDL), in vitro and in vivo migration towards chemotactic stimuli and in vitro tube formation.

conclusionsThese studies demonstrate that primary CB AC133+ culture contained mainly EPCs and that long term in vitro conditions facilitated the maintenance of these cells in the state of commitment towards endothelial lineage.

Indexed as

AC133 AntigenAnimalsAntigens, CDCell Culture TechniquesCell DifferentiationCell MovementCell ProliferationCells, CulturedEndothelial CellsFemaleFetal BloodFlow CytometryGlycoproteinsHematopoietic Stem CellsHumansImmunophenotypingAC133 AntigenAntigens, CDGlycoproteinsPeptidesPlatelet Endothelial Cell Adhesion Molecule-1PROM1 protein, humanProm1 protein, mousevon Willebrand Factor

Identifiers

PMID20161785
PMCPMC2820083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.